434,200 Shares in Organon & Co. $OGN Acquired by Maven Securities LTD

Key Points

• Maven Securities LTD acquired 434,200 shares of Organon & Co. in the second quarter, valued at approximately $5.88 million and representing about 0.17% of the company.
• Institutional investors own 77.43% of Organon, while analysts maintain a cautious outlook: five rate the stock Hold and two rate it Sell, resulting in a consensus “Reduce” rating and an $11.40 target price.
• Organon shares opened at $13.77, near their 52-week high of $13.78. The company also declared a quarterly dividend of $0.02 per share, equivalent to a 0.6% annualized yield.

Maven Securities LTD purchased a new stake in Organon & Co. (NYSE:OGN - Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The fund purchased 434,200 shares of the company's stock, valued at approximately $5,879,000. Maven Securities LTD owned about 0.17% of Organon & Co. as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Allied Private Wealth LLC acquired a new stake in shares of Organon & Co. during the second quarter worth $33,000. Nykredit A S purchased a new position in Organon & Co. during the second quarter worth about $76,000. GAMMA Investing LLC lifted its position in Organon & Co. by 69.8% during the second quarter. GAMMA Investing LLC now owns 5,782 shares of the company's stock worth $78,000 after buying an additional 2,376 shares during the period. Eurizon Capital SGR S.p.A. purchased a new position in Organon & Co. during the fourth quarter worth about $44,000. Finally, Kestra Advisory Services LLC acquired a new stake in Organon & Co. in the 4th quarter worth about $47,000. Hedge funds and other institutional investors own 77.43% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut Organon & Co. from a "hold (c)" rating to a "hold (c-)" rating in a report on Monday, August 3rd. Five research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Organon & Co. currently has a consensus rating of "Reduce" and a consensus target price of $11.40.

Organon & Co. Stock Performance

NYSE:OGN opened at $13.77 on Wednesday. The company has a market cap of $3.61 billion, a P/E ratio of 17.88, a P/E/G ratio of 1.28 and a beta of 1.52. The firm's 50 day moving average is $13.62 and its two-hundred day moving average is $11.43. Organon & Co. has a fifty-two week low of $5.69 and a fifty-two week high of $13.78. The company has a quick ratio of 1.44, a current ratio of 1.95 and a debt-to-equity ratio of 8.43.

Organon & Co. Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be issued a dividend of $0.02 per share. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Organon & Co.'s dividend payout ratio is presently 10.39%.

Organon & Co. Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.